Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit

Critical Care

Volumn 14, Issue 6, 2010, Pages

  Bassetti, Matteo ^a   Mikulska, Małgorzata ^a   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; BETA DEXTRO GLUCAN; CASPOFUNGIN; CELL MEMBRANE PROTEIN; FLUCONAZOLE; ITRACONAZOLE; MANNAN; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ABDOMINAL SURGERY; ACUTE KIDNEY FAILURE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; BLOOD CULTURE; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER REMOVAL; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DISEASE TRANSMISSION; DRUG THERAPY; EMPIRICAL THERAPY; ESOPHAGUS CANDIDIASIS; FALSE POSITIVE RESULT; FUNGAL COLONIZATION; HEMODIALYSIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; INTENSIVE CARE UNIT; INTRAVASCULAR CATHETER; INVASIVE CANDIDIASIS; KIDNEY FAILURE; LIVER FAILURE; LOADING DRUG DOSE; LOW BIRTH WEIGHT; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NONHUMAN; PANCREATITIS; PARENTERAL NUTRITION; PATIENT IDENTIFICATION; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THERAPY EFFECT; TRANSPLANTATION; TREATMENT DURATION; BLOOD; CANDIDA; DISEASE MANAGEMENT; HOSPITAL INFORMATION SYSTEM; ISOLATION AND PURIFICATION; REVIEW;

CANDIDA; CANDIDIASIS, INVASIVE; DISEASE MANAGEMENT; HUMANS; INTENSIVE CARE UNITS; POINT-OF-CARE SYSTEMS; RISK FACTORS;

EID: 82555188408     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9239     Document Type: Article

References (76)

1. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O, . AmarCand Study Group Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37:1612-1618. 10.1097/CCM.0b013e31819efac0, 19325476, AmarCand Study Group.
2. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, . Micafungin Invasive Candidiasis Working Group Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527. 10.1016/S0140-6736(07)60605-9, 17482982, Micafungin Invasive Candidiasis Working Group.
3. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ, . Anidulafungin Study Group Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482. 10.1056/NEJMoa066906, 17568028, Anidulafungin Study Group.
4. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP, . National Epidemiology of Mycoses Survey(NEMIS) Study Group Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33:177-186. 10.1086/321811, 11418877, National Epidemiology of Mycoses Survey(NEMIS) Study Group.
5. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995, 20:1526-1530.
6. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospitalacquired candidemia. A matched case-control study. Arch Intern Med 1989, 149:2349-2353. 10.1001/archinte.149.10.2349, 2802900.
7. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000, 21:510-515. 10.1086/501795, 10968716.
8. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177. 10.1086/378745, 14557960.
9. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002, 45:141-145. 10.1046/j.1439-0507.2002.00741.x, 12100528.
10. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232-1239. 10.1086/496922, 16206095.
11. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from populationbased candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26:540-547. 10.1086/502581, 16018429.
12. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, Fridkin SK, Pappas PG, Warnock DW. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005, 43(Suppl 1):S49-S58. 10.1080/13693780400020113, 16110792.
13. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31. 10.1086/504810, 16758414.
14. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645. 1195428, 16127033, 10.1128/AAC.49.9.3640-3645.2005.
15. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703. 10.1086/599039, 19441981.
16. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007, 60:613-618. 10.1093/jac/dkm212, 17576697.
17. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317. 10.1086/421946, 15306996.
18. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3:685-702. 10.1016/S1473-3099(03)00801-6, 14592598.
19. Magnason S, Kristinsson KG, Stefansson T, Erlendsdottir H, Jonsdottir K, Kristjansson M, Jonmundsson E, Baldursdottir L, Sigvaldason H, Gudmundsson S. Risk factors and outcome in ICU-acquired infections. Acta Anaesthesiol Scand 2008, 52:1238-1245. 10.1111/j.1399-6576.2008.01763.x, 18823463.
20. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, Dupont H. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009, 63:785-794. 10.1093/jac/dkp005, 19196742.
21. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002, 40:1298-1302. 140380, 11923348, 10.1128/JCM.40.4.1298-1302.2002.
22. Passos XS, Costa CR, Araujo CR, Nascimento ES, e Souza LK, Fernandes Ode F, Sales WS, Silva Mdo R. Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital. Mycopathologia 2007, 163:145-151. 10.1007/s11046-007-0094-5, 17334813.
23. Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ, Kollef MH. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007, 35:1077-1083. 10.1097/01.CCM.0000259379.97694.00, 17312565.
24. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006, 10:21.
25. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S. Factors associated with candidemia caused by nonalbicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008, 46:1206-1213. 10.1086/529435, 18444857.
26. Klingspor L, Tornqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004, 36:52-55. 10.1080/00365540310017447, 15000560.
27. Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004, 39(Suppl 4):S185-S192. 10.1086/421955, 15546116.
28. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, Torres-Rodriguez JM. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997, 23:23-30. 10.1007/s001340050286, 9037636.
29. Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF. Candidemia in intensive care unit patients: risk factors for mortality. Infection 1997, 25:8-11. 10.1007/BF02113499, 9039530.
30. Pereira GH, Muller PR, Szeszs MW, Levin AS, Melhem MS. Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans Candida species. Med Mycol 2010, 48:839-842. 10.3109/13693780903580121, 20163281.
31. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 2002, 50:243-260. 10.1053/jhin.2001.1151, 12014897.
32. Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect 2008, 14:136-140. 10.1111/j.1469-0691.2007.01892.x, 18042196.
33. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630. 10.1086/342300, 12173140.
34. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008, 106:523-529. table of contents, 10.1213/ane.0b013e3181607262, 18227310.
35. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999, 28:1071-1079. 10.1086/514731, 10452637.
36. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996, 22(Suppl 2):S89-S94.
37. Asmundsdottir LR, Erlendsdottir H, Haraldsson G, Guo H, Xu J, Gottfredsson M. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008, 47:e17-e24. 10.1086/589298, 18549311.
38. Bliss JM, Basavegowda KP, Watson WJ, Sheikh AU, Ryan RM. Vertical and horizontal transmission of Candida albicans in very low birth weight infants using DNA fingerprinting techniques. Pediatr Infect Dis J 2008, 27:231-235. 10.1097/INF.0b013e31815bb69d, 18277930.
39. Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991, 13:211-215.
40. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220:751-758. 1234477, 7986142, 10.1097/00000658-199412000-00008.
41. Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, Leon MA. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34:730-737. 10.1097/01.CCM.0000202208.37364.7D, 16505659.
42. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007, 26:271-276. 10.1007/s10096-007-0270-z, 17333081.
43. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?. Crit Care Med 2003, 31:752-757. 10.1097/01.CCM.0000053525.49267.77, 12626979.
44. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, . Infectious Diseases Society of America Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635, Infectious Diseases Society of America.
45. Presterl E, Parschalk B, Bauer E, Lassnigg A, Hajdu S, Graninger W. Invasive fungal infections and (1,3)-β-D-glucan serum concentrations in long-term intensive care patients. Int J Infect Dis 2009, 13:707-712. 10.1016/j.ijid.2008.10.013, 19157947.
46. Guery BP, Arendrup MC, Qzinger G, Azoulay E, Borges Sá M, Johnson EM, Müller E, Putensen C, Rotstein C, Sganga G, Venditti M, Zaragoza Crespo R, Kullberg BJ. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 2009, 35:55-62. 10.1007/s00134-008-1338-7, 18972101.
47. Lipsett PA. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin Infect Dis 2004, 39(Suppl 4):S193-S199. 10.1086/421956, 15546117.
48. Cruciani M, de Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005, 31:1479-1487. 10.1007/s00134-005-2794-y, 16172847.
49. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005, 33:1928-1935. quiz 1936, 10.1097/01.CCM.0000178352.14703.49, 16148461.
50. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006, 57:628-638. 10.1093/jac/dki491, 16459344.
51. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001, 32:1191-1200. 10.1086/319763, 11283809.
52. Edwards JE, Bodey GP, Bowden RA, Büchner T, de PQw BE, Filler SG, Ghannoum MA, GlQser M, Herbrecht R, KQffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Rogers TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997, 25:43-59. 10.1086/514504, 9243032.
53. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34:730-751. 10.1086/339215, 11850858.
54. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002, 28:1708-1717. 10.1007/s00134-002-1540-y, 12447512.
55. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001, 233:542-548. 1421284, 11303137, 10.1097/00000658-200104000-00010.
56. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999, 27:1066-1072. 10.1097/00003246-199906000-00019, 10397206.
57. Bassetti M, Ansaldi F, Nicolini L, Malfatto E, Molinari MP, Mussap M, Rebesco B, Bobbio Pallavicini F, Icardi G, Viscoli C. Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother 2009, 64:625-629. 10.1093/jac/dkp251, 19622536.
58. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004, 23:739-744. 10.1007/s10096-004-1215-4, 15372315.
59. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005, 41:1242-1250. 10.1086/496927, 16206097.
60. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, Boillot A. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004, 32:2443-2449. 10.1097/01.CCM.0000147726.62304.7F, 15599149.
61. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659. 10.1086/432470, 16080087.
62. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008, 56:126-129. 10.1016/j.jinf.2007.10.014, 18082269.
63. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:1-45. 10.1086/599376, 19489710.
64. Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, Kovanda L, Lortholary O. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010, 51:295-303. 10.1086/653935, 20578829.
65. Lewis RE, Kontoyiannis DP, Darouiche RO, Prince RA. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob Agents Chemother 2002, 46:3499-3505. 128760, 12384356, 10.1128/AAC.46.11.3499-3505.2002.
66. Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R, de Gaetano Donati K, La Sorda M, Spanu T, Fadda G, Cauda R, Sanguinetti M. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007, 45:1843-1850. 1933062, 17460052, 10.1128/JCM.00131-07.
67. Choi HW, Shin JH, Jung SI, Park KH, Cho D, Kee SJ, Shin MG, Suh SP, Ryang DW. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 2007, 51:1520-1523. 1855493, 17283191, 10.1128/AAC.01141-06.
68. Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med 2007, 33:1272-1283. 10.1007/s00134-007-0672-5, 17503015.
69. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006, 117:1680-1687. 10.1542/peds.2005-1996, 16651324.
70. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008, 112:2493-2499. 10.1002/cncr.23466, 18412153.
71. Cohen Y, Karoubi P, Adrie C, Gauzit R, Marsepoil T, Zarka D, Clec'h C. Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients. Crit Care Med 2010, 38:826-830. 10.1097/CCM.0b013e3181cc4734, 20042858.
72. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med 1993, 94:577-582. 10.1016/0002-9343(93)90207-6, 8389525.
73. Hernandez-Castro R, Arroyo-Escalante S, Carrillo-Casas EM, Moncada-Barron D, Alvarez-Verona E, Hernandez-Delgado L, Torres-Narvaez P, Lavalle-Villalobos A. Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur J Pediatr 2010, 169:783-787. 10.1007/s00431-009-1109-7, 19957192.
74. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47:3149-3154. 201160, 14506023, 10.1128/AAC.47.10.3149-3154.2003.
75. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010, 36:1-53. 10.3109/10408410903241444, 20088682.
76. De Waele JJ, Vogelaers D, Blot S, Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003, 37:208-213. 10.1086/375603, 12856213.